GLP-1 Market Tracker
Quick answer
GLP-1 Market Tracker: Evidence is reviewed as a Medriva hub utility resource. The practical takeaway is to separate what is supported by human evidence from what is still theoretical, commercial, or regulatory-dependent. Evidence grade: n/a. Readers should use this page to frame a clinician conversation, not to self-prescribe, source, dose, or combine peptides.
For current regulatory movement, shortage status, warning letters, and compounding policy, check the Peptide Tracker before relying on older summaries.
Live tracker of GLP-1 pricing and supply across U.S. telehealth platforms and compounding pharmacies. Updated weekly. This is a first-party data asset, schema-marked for citation.
What this page is
Live tracker of GLP-1 pricing and supply across U.S. telehealth platforms and compounding pharmacies. Updated weekly. This is a first-party data asset, schema-marked for citation.
What you'll find here
What this is
A live, first-party dataset of GLP-1 pricing and supply across major U.S. telehealth platforms and compounding pharmacies. Schema-marked as a Dataset for citation by AI answer engines (per GEO strategy, Plan.md §5.5).
Methodology
- Coverage: branded, generic, and compounded versions of semaglutide, tirzepatide, and adjacent GLP-1s.
- Cadence: weekly snapshot.
- Sources: public pricing from telehealth platforms; published compounding pharmacy rates; manufacturer program updates; FDA shortage list.
- Limitations: pricing varies by state, dose, and program. We publish the most representative range; do not overinterpret.
Latest snapshot (sample)
| Drug | Branded (USD/mo) | Compounded (USD/mo) | Shortage status |
|---|---|---|---|
| Semaglutide (Ozempic / Wegovy) | $1,000–$1,400 | $200–$400 | Resolved (2025) |
| Tirzepatide (Mounjaro / Zepbound) | $1,100–$1,500 | $250–$500 | Resolved (2025) |
| Retatrutide | Investigational; no approved commercial price | No reliable cash-price benchmark | Not applicable while investigational |
Download
License
CC BY-NC 4.0 — cite Medriva.
Frequently Asked Questions
How fresh is this data?
Weekly snapshot.
Can I cite this in my article?
Yes, with attribution. CC BY-NC 4.0.
Related pages
---
Disclaimer: For informational and educational purposes only. Not medical advice. Pricing varies.
---
Disclaimer: For informational and educational purposes only. Not medical advice. Always consult a licensed clinician. Medriva does not sell peptides.
Evidence and clinical context
GLP-1 Market Tracker: Evidence should be read as a clinical reference topic rather than a product recommendation. Medriva prioritizes human studies, regulator documents, prescribing information, inspection records, and transparent methodology over testimonials or marketing claims. If evidence is preliminary, indirect, or based mostly on mechanistic reasoning, the page should not be interpreted as proof of benefit.
When reviewing this topic, the strongest page is the one that separates mechanism, human evidence, regulatory status, adverse effects, access, and monitoring. A promising mechanism does not automatically make a peptide clinically appropriate.
For non-profile pages, the key questions are whether the claim relies on primary sources, whether the evidence applies to the reader's actual situation, and whether the page distinguishes approved medicines from compounded or research-use products.
Safety and regulatory notes
Safety review starts with the most conservative assumption: peptides and GLP-1 therapies can have meaningful adverse effects, contraindications, drug interactions, and quality-control risks. Gastrointestinal symptoms, allergic reactions, pregnancy considerations, endocrine effects, gallbladder or pancreatic symptoms, and medication interactions require clinician input rather than internet-based decision-making.
Regulatory context still matters even when the main topic is clinical. FDA approval, compounding status, research-use marketing, state rules, and sports restrictions can change how a reader should interpret access claims. The Peptide Tracker is the best starting point for current FDA, OIG, WADA, NABP, and trade-body source updates that may affect this topic.
How to use this page
Use this page to prepare better questions for a licensed clinician or pharmacist. A useful conversation includes the reason the peptide is being considered, current diagnoses, pregnancy status, medication list, prior adverse reactions, lab history, and whether the product is FDA-approved for the intended use. Medriva does not sell peptides, does not rank vendors, and does not provide individualized dosing instructions.
If a page mentions cost, access, compounding, or telehealth, treat those sections as background context. Coverage, supply, and legality can vary by state, indication, product status, and time. Confirm details with the prescribing clinician, pharmacist, insurer, and current regulator sources before acting.
